MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
En‐Chi Hsu(National Health Research Institutes), Tanya Stoyanova(Stanford University)
Cited by 32
Related Papers
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
|Cancer Cell|2016|416
Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling
|Genes & Development|2012|149
Oncogene-mediated metabolic gene signature predicts breast cancer outcome
|npj Breast Cancer|2021|62
Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer
|Proceedings of the National Academy of Sciences|2016|49
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas
|Cell Reports Medicine|2024|29